PROSPECTIVE METHODS OF VITILIGO TREATMENT (LITERATURE REVIEW)

Abstract

A systematic review of modern methods of treatment of vitiligo is presented. Treatment of vitiligo is a difficult task. The data of various studies are shown. It has been revealed that during the treatment of associated diseases, positive effects of vitiligo in the form of pigmentation recovery from some drugs are noticed. Therefore, many drugs are considered not only as promising vitiligo treatment, but also as independent. The purpose of this article is to update information in the treatment of vitiligo, including existing and new methods.

Keywords

vitiligo / treatment of vitiligo / review / minocycline / methotrexate / afamelanocid / simvastatin / inhibitors of Janus kinases

References

[1] Nordlund J.J. Vitiligo: a review of some facts lesser known about depigmentation. Indian J. Dermatol. 2011; 56(2): 180-9.

[2] Grimes P.E. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J. Am. Acad. Dermatol. 2004; 51(1, Suppl.): S5-7.

[3] Spritz R.A. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J. Invest. Dermatol. 2012; 132(2): 268-73.

[4] Grimes P.E. Disorders of pigmentation. In: Dale D.C., Federman D.D., eds. ACP Medicine. New York: WebMD; 2012: 544-54.

[5] Minder E.I., Barman-Aksoezen J., Schneider-Yin X. Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders. Clin. Pharmacokinet. 2017; 56(8): 815-23.

[6] Lim H.W., Grimes P.E., Agbai O., Hamzavi I., Henderson M., Haddican M., et al. Afamelanotide and narrowband UVB phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015; 151(1): 42-50.

[7] Grimes P.E., Hamzavi I., Lebwohl M., Ortonne J.P., Lim H.W. The efficacy of afamelanotide and narrowband UVB phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013; 149(1): 68-73.

[8] Kraus R.L., Pasieczny R., Lariosa-Willingham K., Turner M.S., Jiang A., Trauger J.W. Antioxidant properties of minocycline: neuroprotection in an oxidative stressassay and direct radical-scavenging activity. J. Neurochem. 2005; 94(3): 819-27.

[9] Song X., Xu A., Pan W., Wallin B., Kivlin R., Lu S., et al. Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways. Int. J. Mol. Med. 2008; 22(1): 9-16.

[10] Parsad D., Kanwar A. Oral minocycline in the treatment of vitiligo - a preliminary study. Dermatol. Ther. 2010; 23(3): 305-7.

[11] Singh A., Kanwar A.J., Parsad D., Mahajan R. Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian J. Dermatol. Venereol. Leprol. 2014; 80(1): 29-35.

[12] Siadat A.H., Zeinali N., Iraji F., Abtahi-Naeini B., Nilforoushzadeh M.A., Jamshidi K., Khosravani P. Narrow-band ultraviolet B versus oral minocycline in treatment of unstable vitiligo: a prospective comparative trial. Dermatol. Res. Pract. 2014; 2014: 240856.

[13] Singh H., Kumaran M.S., Bains A., Parsad D. A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology. 2015; 231(3): 286-90.

[14] Garza-Mayers A.C., Kroshinsky D. Low-dose methotrexate for vitiligo. J. Drugs Dermatol. 2017; 16(7): 705-6.

[15] Noel M., Gagne C., Bergeron J., Jobin J., Poirier P. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis. 2004; 3: 7.

[16] Agarwal P., Rashighi M., Essien K.I., Richmond J.M., Randall L., Pazoki-Toroudi H., et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. J. Invest. Dermatol. 2015; 135(4): 1080-8.

[17] Kavalipati N., Shah J., Ramakrishan A., Vasnawala H. Pleiotropic effects of statins. Indian J. Endocrinol. Metab. 2015; 19(5): 554-62.

[18] Zhou Q., Liao J.K. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharm. Des. 2009; 15(5): 467-78.

[19] Niezgoda A., Winnicki A., Kosmalski T., Kowaliszyn B., Krysinski J., Czajkowski R. The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial. Trials. 2019; 20(1): 78. doi: 10.1186/s13063-018-3168-4.

[20] Frisoli M.L., Harris J.E. Vitiligo: mechanistic insights lead to novel treatments. J. Allergy Clin. Immunol. 2017; 140(3): 654-62.

[21] Craiglow B.G., King B.A. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015; 151(10): 1110-2.

[22] Harris J.E., Rashighi M., Nguyen N., Jabbari A., Ulerio G., Clynes R., et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J. Am. Acad. Dermatol. 2016; 74(2): 370-1.

[23] Rothstein B., Joshipura D., Saraiya A., Abdat R., Ashkar H., Turkowski Y., et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J. Am. Acad. Dermatol. 2017; 76(6): 1054-60.

[24] Liu L.Y., Strassner J.P., Refat M.A., Harris J.E., King B.A. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J. Am. Acad. Dermatol. 2017; 77(4): 675-82.

[25] Fernandez-Obregon A.C. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo. J. Drugs Dermatol. 2008; 7(7): 679-81.

RIGHTS & PERMISSIONS

Eco-Vector